3-(3-溴吡啶-4-基)丙酸乙酯 | 463303-98-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 3-(3-溴吡啶-4-基)丙酸乙酯
• 英文名称: 3-(3-bromo-4-pyridyl)propionic acid ethyl ester
• 英文别名: 3-(3-bromopyridin-4-yl)propionate ethyl ester；ethyl 3-(3-bromo-4-pyridyl)propanoate；Ethyl 3-(3-bromopyridin-4-yl)propanoate
• CAS: 463303-98-2
• 化学式: C₁₀H₁₂BrNO₂
• 分子量: 258.115
• InChiKey: PWPSJLOTMHDOAC-UHFFFAOYSA-N

物化性质

• 沸点：
  313.7±27.0 °C(Predicted)
• 密度：
  1.397±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3-(3-溴吡啶-4-基)丙酸乙酯 在 盐酸 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 13.0h， 生成 3-bromo-4-[2-(4,5-dihydro-3H-pyrrol-2-yl)ethyl]pyridine
  参考文献：
  名称：

  Conformationally Constrained Nicotines:  Polycyclic, Bridged, and Spiro-Annulated Analogues as Novel Ligands for the Nicotinic Acetylcholine Receptor

  摘要：

  A set of novel nicotine-related, conformationally constrained compounds, including tetracyclic, bridged (4), and tricyclic, spiro-annulated (5) structures, were synthesized in a straightforward manner and optically resolved in a convenient fashion with (+)- and (-)-O,O'-di-p-toluoyltartaric acids. Absolute configurations were determined by X-ray crystallography. These compounds were evaluated for their ability to displace [H-3]cytisine in a rat forebrain preparation and compared to (-)-nicotine. Three substances emerged with high affinity in the low nanomolar range. Moreover, one of these compounds ((+)-5b) showed not only high binding affinity (K-i = 4.79 nM) but also significant enantioselectivity over its antipode (K-i = 148 nM), supporting the hypothesis that conformational restraint can lead to high-affinity ligands, which are stereochemically discriminated by the nicotinic acetylcholine receptor and may feature optimum locations of the active sites of the pharmacophore.

  DOI：

  10.1021/jm020916b
• 作为产物：
  描述：

  3-溴吡啶 在 lithium chloride 、 锌 作用下， 以 四氢呋喃 为溶剂， 反应 73.0h， 生成 3-(3-溴吡啶-4-基)丙酸乙酯
  参考文献：
  名称：

  Conformationally Constrained Nicotines:  Polycyclic, Bridged, and Spiro-Annulated Analogues as Novel Ligands for the Nicotinic Acetylcholine Receptor

  摘要：

  A set of novel nicotine-related, conformationally constrained compounds, including tetracyclic, bridged (4), and tricyclic, spiro-annulated (5) structures, were synthesized in a straightforward manner and optically resolved in a convenient fashion with (+)- and (-)-O,O'-di-p-toluoyltartaric acids. Absolute configurations were determined by X-ray crystallography. These compounds were evaluated for their ability to displace [H-3]cytisine in a rat forebrain preparation and compared to (-)-nicotine. Three substances emerged with high affinity in the low nanomolar range. Moreover, one of these compounds ((+)-5b) showed not only high binding affinity (K-i = 4.79 nM) but also significant enantioselectivity over its antipode (K-i = 148 nM), supporting the hypothesis that conformational restraint can lead to high-affinity ligands, which are stereochemically discriminated by the nicotinic acetylcholine receptor and may feature optimum locations of the active sites of the pharmacophore.

  DOI：

  10.1021/jm020916b

文献信息

• 羧酸化合物及其制备方法和用途
  申请人：益方生物科技（上海）有限公司

  公开号：CN105439946B

  公开（公告）日：2018-02-02

  本发明涉及医药技术领域，具体为由以下化学式I或化学式II表示的羧酸化合物及其药学上可接受的盐、前药、和溶剂化物及其制备方法，包含这些物质的药物组合物以及其用途。
• [EN] PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRROLOPYRIDAZINE UTILISÉS COMME INHIBITEURS DE KINASE
  申请人：GOSSAMER BIOSERVICES INC

  公开号：WO2022109492A1

  公开（公告）日：2022-05-27

  Described herein are inhibitors of JAK kinases, pharmaceutical compositions comprising them, processes for preparing them and uses of such inhibitors to treat or prevent diseases, disorders and conditions associated with kinase function.

  本文描述了JAK激酶抑制剂，包括它们的制药组合物、制备它们的过程以及使用这些抑制剂来治疗或预防与激酶功能相关的疾病、紊乱和病况。
• [EN] CARBOXYLIC ACID COMPOUND, METHOD FOR PREPARATION THEREOF, AND USE THEREOF<br/>[FR] COMPOSÉ D'ACIDE CARBOXYLIQUE, PROCÉDÉ DE PRÉPARATION ET UTILISATION ASSOCIÉS<br/>[ZH] 羧酸化合物及其制备方法和用途
  申请人：SHANGHAI SHALETECH TECHNOLOGY CO LTD

  公开号：WO2016023460A1

  公开（公告）日：2016-02-18

  本发明涉及医药技术领域，具体为由以下化学式I或化学式II表示的羧酸化合物及其药学上可接受的盐、前药、和溶剂化物及其制备方法，包含这些物质的药物组合物以及其用途。
• CARBOXYLIC ACID COMPOUND, METHOD FOR PREPARATION THEREOF, AND USE THEREOF
  申请人：Shanghai Shaletech Technology Co., Ltd.

  公开号：EP3181557A1

  公开（公告）日：2017-06-21

  The present invention relates to the technical field of medicine, and specifically relates to the carboxylic acid compound represented by the chemical formula I or chemical formula II, and a pharmaceutically acceptable salt, a prodrug, and a solvate thereof, and a method for preparation thereof, as well as a pharmaceutical composition containing the described substances, and a use thereof.

  本发明涉及医药技术领域，具体涉及化学式 I 或化学式 II 所代表的羧酸化合物及其药学上可接受的盐、原药和溶液及其制备方法，以及含有所述物质的药物组合物及其用途。
• US9809580B2
  申请人：——

  公开号：US9809580B2

  公开（公告）日：2017-11-07